TAMPA, FL — (MARKET WIRE) — May 29, 2007 — Stem Cell Therapy International, Inc. , a leading stem cell research company operating international treatment clinics, announced today that it has been contacted by representatives for companies in India, Australia and Indonesia regarding acquiring the technology and license rights to SCII’s new “no scars” stem cell treatment for burn patients. “We have prepared and submitted drafts of our licensing proposal including our standard $1 million initial fee per country in addition to a negotiated royalty per treatment,” said Calvin Cao, president and CEO of Stem Cell Therapy International. “Our proprietary, patent pending, ‘no scars’ stem cell treatment for burn victims is just one of several different cutting-edge stem cell treatments that SCII has developed and is now able to license to physicians and medical groups around the world. We are just getting started to expand our current treatment clinics in the Ukraine, Mexico and China to an additional 9 countries,” stated Cao, who began his trip on Sunday to conduct onsite inspections with current affiliates in China and proposed new affiliates in India. Mr. Cao recently returned from an onsite inspection trip for a planned new affiliate treatment clinic in Costa Rica. The discussions with the groups from Australia and Indonesia will be continued by the company’s legal counsel for licensing, Gerald R. Newman, Esq., while Mr. Cao is on his business travels.
About Stem Cell Therapy International
Stem Cell Therapy International, Inc. is engaged in the field of regenerative medicine. This includes ongoing research, development and the use of stem cell transplantation therapy for those suffering from degenerative disorders such as Alzheimer’s, Parkinson’s disease, ALS, leukemia, muscular dystrophy, multiple sclerosis, arthritis, spinal cord injuries, brain injury, stroke, heart disease, liver failure, retinal disease and diabetes. The company has established affiliate agreements with highly specialized, professional medical treatment facilities in various worldwide locations where stem cell transplantation therapy by licensed physicians is approved for patient use in those jurisdictions. With its leading edge treatment clinics in countries now allowing stem cell treatments, and thus generating current revenues, the company also plans to gain a presence in the U.S. market, as an additional revenue source, as soon as stem cell procedures are approved by the FDA. For further information visit the company’s website www.SCTIcorp.com